PresseBox
Press release BoxID: 157208 (UCB Pharma GmbH)
  • UCB Pharma GmbH
  • Alfred-Nobel-Str. 10
  • 40789 Monheim
  • http://www.ucb.com/
  • Contact person
  • Sylvia Heitzer
  • +49 (2173) 48-1238

Full Year Report 2007

Integration of SCHWARZ PHARMA Business into UCB Group on Target

(PresseBox) (Monheim, ) Within the course of the integration process, a large share of SCHWARZ PHARMA AG’s foreign business was transferred to the UCB Group. At the end of fiscal year 2007, 13 affiliates ceased to belong to the scope of consolidation of SCHWARZ PHARMA AG. Hence the presented business figures (preliminary and unaudited) show the results of the continued business activities of the remaining consolidated companies. The latter achieved net sales of EUR 327.3 million in 2007 compared to EUR 362.1 million in the previous year ( 9.6%). SCHWARZ PHARMA expects a sales increase in fiscal year 2008.

For more information, please see our website: http://www.schwarzpharma.com/sp/n192/Interim_Reports/

This press release contains assumptions, expectations, and forecasts on future sector trends, on future legal and commercial developments, and on the future development of the company. These assumptions, expectations, and forecasts are no guarantee for future performance and are subject to change at any time. Consequently, future reports and the factual circumstances of the company may deviate materially from the outlook presented by the above. The company assumes no responsibility for updating such assumptions, expectations, and forecasts on future sector trends, on future legal and commercial developments, and on the future development of the company.

UCB Pharma GmbH

SCHWARZ PHARMA AG (seated in Monheim, Germany) is a company of the UCB Group, Brussels/Belgium (www.ucb-group.com). UCB is listed on the Euronext exchange in Brussels and holds around 89% of all SCHWARZ PHARMA shares.
UCB is a leading global biopharmaceutical company whose focus is on researching, developing, and commercializing innovative pharmaceutical and biotechnological products in the fields Central Nervous System, allergic and respiratory diseases, immunological and inflammatory diseases, and oncology. UCB achieved sales of €3.6 billion (pro forma) in 2007 and employs more than 11.000 workers in 40 countries.